Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016
Published Jun 15, 2016
72 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016, provides an overview of the Systemic Idiopathic Juvenile Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis
- The report reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Systemic Idiopathic Juvenile Arthritis therapeutics and enlists all their major and minor projects
- The report assesses Systemic Idiopathic Juvenile Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively

  
Source:
Document ID
GMDHC8199IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Systemic Idiopathic Juvenile Arthritis Overview71
Therapeutics Development81
  Pipeline Products for Systemic Idiopathic Juvenile Arthritis Overview81
Systemic Idiopathic Juvenile Arthritis Therapeutics under Development by Companies91
Systemic Idiopathic Juvenile Arthritis Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Systemic Idiopathic Juvenile Arthritis Products under Development by Companies131
Systemic Idiopathic Juvenile Arthritis Companies Involved in Therapeutics Development148
  Alteogen Inc.141
  Bristol-Myers Squibb Company151
  Epirus Biopharmaceuticals, Inc.161
  Johnson &Johnson171
  Momenta Pharmaceuticals, Inc.181
  Mycenax Biotech Inc.191
  Novartis AG201
  Oncobiologics, Inc.211
Systemic Idiopathic Juvenile Arthritis Therapeutics Assessment229
  Assessment by Monotherapy Products221
  Assessment by Target232
  Assessment by Mechanism of Action252
  Assessment by Route of Administration272
  Assessment by Molecule Type292
Drug Profiles3128
  abatacept Drug Profile315
  abatacept biosimilar Drug Profile361
  abatacept biosimilar Drug Profile371
  adalimumab biosimilar Drug Profile382
  adalimumab biosimilar Drug Profile401
  adalimumab biosimilar Drug Profile411
  adalimumab biosimilar Drug Profile421
  canakinumab Drug Profile435
  golimumab Drug Profile488
  tocilizumab biosimilar Drug Profile561
  tocilizumab biosimilar Drug Profile571
  tocilizumab biosimilar Drug Profile581
Systemic Idiopathic Juvenile Arthritis Dormant Projects591
Systemic Idiopathic Juvenile Arthritis Discontinued Products601
Systemic Idiopathic Juvenile Arthritis Product Development Milestones6110
  Featured News &Press Releases611
    Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis611
    Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris621
    May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis631
    Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials642
    Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting661
    Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012672
    Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis692
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Systemic-Idiopathic-Juvenile-Arthritis-Pipeline-Review-H1-2016-2088-15953>
  
APA:
Global Markets Direct - Market Research. (2016). Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Systemic-Idiopathic-Juvenile-Arthritis-Pipeline-Review-H1-2016-2088-15953>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.